prof. RNDr. Zbyněk Zdráhal, Dr.
Research Group Leader Senior, Zbyněk Zdráhal Research Group
Office: bldg. E26/108
Kamenice 753/5
625 00 Brno
Phone: | +420 549 49 8258 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 368
2014
-
Functional Analysis of Dishevelled-3 Phosphorylation Identifies Distinct Mechanisms Driven by Casein Kinase 1 epsilon and Frizzled5
Journal of Biological Chemistry, year: 2014, volume: 289, edition: 34, DOI
-
H3K56ac distribution in cancer and embryonic cell lines during cell cycle
Year: 2014, type: Conference abstract
-
Huwe1-mediated ubiquitylation of dishevelled defines a negative feedback loop in the wnt signaling pathway.
Science Signaling, year: 2014, volume: 7, edition: 317, DOI
-
Improvement in Staphylococcus and Bacillus strain differentiation by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling by using microwave-assisted enzymatic digestion
Rapid Communications in Mass Spectrometry, year: 2014, volume: 28, edition: 17, DOI
-
In search of ligands and receptors of the pollen tube: the missing link in pollen tube perception
BIOCHEMICAL SOCIETY TRANSACTIONS, year: 2014, volume: 42, edition: April, DOI
-
Monensin Inhibits Canonical Wnt Signaling in Human Colorectal Cancer Cells and Suppresses Tumor Growth in Multiple Intestinal Neoplasia Mice
Molecular Cancer Therapeutics, year: 2014, volume: 13, edition: 4, DOI
-
No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia
Hematological Oncology, year: 2014, volume: 32, edition: 2, DOI
-
The influence of culture conditions on the identification of Mycobacterium species by MALDI-TOF MS profiling
FEMS Microbiology Letters, year: 2014, volume: 353, edition: 1, DOI
-
The protein composition of excretory-secretory products of three Trichinella species
Year: 2014, type: Conference abstract
2013
-
Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
American Journal of Hematology, year: 2013, volume: 88, edition: 5, DOI